• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质母细胞瘤的异质性与癌细胞可塑性。

Glioblastoma heterogeneity and cancer cell plasticity.

作者信息

Friedmann-Morvinski Dinorah

机构信息

Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California; Department of Biochemistry and Molecular Biology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.

出版信息

Crit Rev Oncog. 2014;19(5):327-36. doi: 10.1615/critrevoncog.2014011777.

DOI:10.1615/critrevoncog.2014011777
PMID:25404148
Abstract

Glioblastoma (GBM) is the most common and malignant type of primary brain tumor. It represents one of the deadliest human cancers, with an average survival at diagnosis of about 1 year. This poor prognosis is due to therapeutic resistance and tumor recurrence after surgical removal. One of the most important hallmarks of GBM is tumor heterogeneity. Intertumor heterogeneity is mostly characterized by distinct genetic alterations that occur in individual tumors originating in the same organ and allows the classification of these tumors into different molecular subtypes. Intratumor heterogeneity-the diversity within individual tumors-has become the focus of research interest in the past few years, and tumor cell plasticity as a new source of cancer stem cells has added another level of complexity to this phenomenon. This review describes the molecular heterogeneity of GBMs at the transcriptome level and the expression profile-based classification of histopathologically indistinguishable tumors into different subtypes. In addition, the role of dedifferentiation of tumor cells into a stem cell-like state is discussed as a source of cellular heterogeneity within tumors, highlighting tumor cell plasticity as an important driver of GBM heterogeneity. Understanding tumor heterogeneity will help design better therapies against GBM and avoid tumor recurrence.

摘要

胶质母细胞瘤(GBM)是最常见且恶性程度最高的原发性脑肿瘤类型。它是最致命的人类癌症之一,诊断后的平均生存期约为1年。这种不良预后归因于治疗抵抗以及手术切除后肿瘤复发。GBM最重要的特征之一是肿瘤异质性。肿瘤间异质性主要表现为源自同一器官的单个肿瘤中发生的不同基因改变,并使这些肿瘤能够被分类为不同的分子亚型。肿瘤内异质性——单个肿瘤内部的多样性——在过去几年中已成为研究热点,而肿瘤细胞可塑性作为癌症干细胞的新来源,为这一现象增添了另一层复杂性。本综述描述了GBM在转录组水平的分子异质性,以及基于表达谱将组织病理学上难以区分的肿瘤分类为不同亚型的情况。此外,还讨论了肿瘤细胞去分化为干细胞样状态作为肿瘤内细胞异质性来源的作用,强调肿瘤细胞可塑性是GBM异质性的重要驱动因素。了解肿瘤异质性将有助于设计出更好的针对GBM的治疗方法并避免肿瘤复发。

相似文献

1
Glioblastoma heterogeneity and cancer cell plasticity.胶质母细胞瘤的异质性与癌细胞可塑性。
Crit Rev Oncog. 2014;19(5):327-36. doi: 10.1615/critrevoncog.2014011777.
2
Dissecting inherent intratumor heterogeneity in patient-derived glioblastoma culture models.剖析患者来源的胶质母细胞瘤培养模型中固有的肿瘤内异质性。
Neuro Oncol. 2017 Jun 1;19(6):820-832. doi: 10.1093/neuonc/now253.
3
Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.Sox2是一种干性基因,可调节CD133阳性胶质母细胞瘤干细胞中的肿瘤起始和耐药特性。
J Chin Med Assoc. 2016 Oct;79(10):538-45. doi: 10.1016/j.jcma.2016.03.010. Epub 2016 Aug 13.
4
Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance.胶质母细胞瘤干细胞的多层次异质性:生物学和临床意义。
Adv Exp Med Biol. 2019;1139:1-21. doi: 10.1007/978-3-030-14366-4_1.
5
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors.胶质母细胞瘤和脑肿瘤中的癌细胞异质性与可塑性
Semin Cancer Biol. 2022 Jul;82:162-175. doi: 10.1016/j.semcancer.2021.02.014. Epub 2021 Feb 25.
6
Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance.电离辐射通过生存素维持胶质母细胞瘤细胞去分化为干细胞样表型:可能与放射抗性有关。
Cell Death Dis. 2014 Nov 27;5(11):e1543. doi: 10.1038/cddis.2014.509.
7
Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes.脑肿瘤起始细胞系的前体细胞状态可预测异种移植物中的存活情况,并与神经胶质瘤亚型相关。
Stem Cell Reports. 2015 Jul 14;5(1):1-9. doi: 10.1016/j.stemcr.2015.05.010. Epub 2015 Jun 18.
8
Stem cell signature in glioblastoma: therapeutic development for a moving target.胶质母细胞瘤中的干细胞特征:针对动态靶点的治疗进展
J Neurosurg. 2015 Feb;122(2):324-30. doi: 10.3171/2014.9.JNS132253. Epub 2014 Nov 14.
9
Comparison of glioblastoma (GBM) molecular classification methods.胶质母细胞瘤(GBM)分子分类方法的比较。
Semin Cancer Biol. 2018 Dec;53:201-211. doi: 10.1016/j.semcancer.2018.07.006. Epub 2018 Jul 19.
10
TGFβ-Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme.转化生长因子β反应性血红素加氧酶1表达与多形性胶质母细胞瘤的干性和侵袭性相关。
Stem Cells. 2016 Sep;34(9):2276-89. doi: 10.1002/stem.2411. Epub 2016 Jul 4.

引用本文的文献

1
Oncolytic Therapies for Glioblastoma: Advances, Challenges, and Future Perspectives.胶质母细胞瘤的溶瘤疗法:进展、挑战与未来展望
Cancers (Basel). 2025 Aug 1;17(15):2550. doi: 10.3390/cancers17152550.
2
Cytomegalovirus-induced oncomodulation drives immune escape in glioblastoma.巨细胞病毒诱导的肿瘤调节促进胶质母细胞瘤的免疫逃逸。
Sci Rep. 2025 Jul 17;15(1):25981. doi: 10.1038/s41598-025-10107-w.
3
Utilizing Monocarboxylate Transporter 1-Mediated Blood-Brain Barrier Penetration for Glioblastoma Positron Emission Tomography Imaging with 6-[F]Fluoronicotinic Acid.
利用单羧酸转运体1介导的血脑屏障穿透作用,用6-[F]氟烟酸进行胶质母细胞瘤正电子发射断层扫描成像。
Mol Pharm. 2025 Aug 4;22(8):4819-4830. doi: 10.1021/acs.molpharmaceut.5c00457. Epub 2025 Jul 3.
4
Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT).通过体外药物筛选实现胶质母细胞瘤个性化靶向治疗:高级脑肿瘤治疗临床试验(ATTRACT)研究方案
Neurooncol Adv. 2025 Mar 7;7(1):vdaf056. doi: 10.1093/noajnl/vdaf056. eCollection 2025 Jan-Dec.
5
Inferred developmental origins of brain tumors from single-cell RNA-sequencing data.从单细胞RNA测序数据推断脑肿瘤的发育起源
Neurooncol Adv. 2025 Jan 23;7(1):vdaf016. doi: 10.1093/noajnl/vdaf016. eCollection 2025 Jan-Dec.
6
Mouse Model of Viral-Induced Brain Tumor and Generation of a Stable Tumor-Derived Cell Line.病毒诱导性脑肿瘤的小鼠模型及稳定的肿瘤衍生细胞系的建立
Methods Mol Biol. 2025;2926:63-72. doi: 10.1007/978-1-0716-4542-0_6.
7
Current Landscape of Therapeutic Cancer Vaccines.治疗性癌症疫苗的当前态势
Methods Mol Biol. 2025;2926:1-14. doi: 10.1007/978-1-0716-4542-0_1.
8
Enhancing clinical decision-making: An externally validated machine learning model for predicting isocitrate dehydrogenase mutation in gliomas using radiomics from presurgical magnetic resonance imaging.增强临床决策:一种经过外部验证的机器学习模型,用于利用术前磁共振成像的影像组学预测胶质瘤中的异柠檬酸脱氢酶突变。
Neurooncol Adv. 2024 Oct 3;6(1):vdae157. doi: 10.1093/noajnl/vdae157. eCollection 2024 Jan-Dec.
9
Multimodal treatment of glioblastoma with multiple lesions - a multi-center retrospective analysis.多灶性胶质母细胞瘤的多模式治疗——一项多中心回顾性分析
J Neurooncol. 2024 Dec;170(3):555-566. doi: 10.1007/s11060-024-04810-3. Epub 2024 Nov 19.
10
Leveraging multi-omics data to infer regulators of mRNA 3' end processing in glioblastoma.利用多组学数据推断胶质母细胞瘤中mRNA 3'端加工的调控因子。
Front Mol Biosci. 2024 Aug 12;11:1363933. doi: 10.3389/fmolb.2024.1363933. eCollection 2024.